Design of Polymeric Nanocapsules for Intranasal Vaccination against Mycobacterium Tuberculosis: Influence of the Polymeric Shell and Antigen Positioning

• Main Authors: Lara Diego-González, José Crecente-Campo, Matthew John Paul, Mahavir Singh, Rajko Reljic, María José Alonso, África González-Fernández, Rosana Simón-Vázquez
• Format: Article
• Language: English
• Published: MDPI AG 2020-05-01
• Series: Pharmaceutics
• Subjects: 6 kDa early secretory antigenic target (ESAT-6); 10 kDa culture filtrate protein (CFP-10); vaccination; Imiquimod; Toll-like receptor-7 (TLR-7); antibodies
• Online Access: https://www.mdpi.com/1999-4923/12/6/489

Tuberculosis (TB) is the leading cause of death from a single infectious microorganism and Bacillus Calmette Guerin (BCG), the only authorized vaccine, does not confer protection against pulmonary TB. Based on the hypothesis that mucosal protection could help to prevent the infection at the site of entrance, the objective of this work was to develop an intranasal vaccine against <i>Mycobacterium tuberculosis </i>(Mtb)<i>, </i>the microorganism that causes TB. Our approach consisted of the use of polymeric nanocapsules (NCs) with an oily core and a polymer shell made of chitosan (CS) or inulin/polyarginine (INU/pArg). The immunostimulant Imiquimod, a Toll-like receptor-7 (TLR-7) agonist, was encapsulated in the oily core and a fusion protein, formed by two antigens of Mtb, was absorbed either onto the NC surface (CS:Ag and INU:pArg:Ag) or between two polymer layers (INU:Ag:pArg) in order to assess the influence of the antigen positioning on the immune response. Although CS NCs were more immunostimulant than the INU/pArg NCs <i>in vitro</i>, the <i>in vivo</i> experiments showed that INU:pArg:Ag NCs were the only prototype inducing an adequate immunoglobulin A (IgA) response. Moreover, a previous immunization with BCG increased the immune response for CS NCs but, conversely, decreased for INU/pArg NCs. Further optimization of the antigen and the vaccination regime could provide an efficacious vaccine, using the INU:pArg:Ag NC prototype as nanocarrier.